AMGN
Price
$468.11Alerts
Change
+$2.88 (+0.62%)
Updated
Nov 11 closing price
Capitalization
248.92B
89 days until earnings call
Intraday BUY SELL Signals
MIRA
Price
$0.62Alerts
Change
-$0.00 (-0.00%)
Updated
Nov 11 closing price
Capitalization
23.97M
Earnings call today
Intraday BUY SELL Signals
Interact to see
Advertisement

AMGN vs MIRA

AMGN vs MIRA Comparison Chart in %
View a ticker or compare two or three
VS
AMGN vs. MIRA commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AMGN is a Buy and MIRA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for AMGN with price predictions
Nov 11, 2026

AMGN in upward trend: 10-day moving average moved above 50-day moving average on October 16, 2026

The 10-day moving average for AMGN crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on AMGN as a result. In 43 of 73 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.

AMGN moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where AMGN advanced for three days, in 194 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.

The Aroon Indicator entered an Uptrend today. In 151 of 272 cases where AMGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.

Bearish Trend Analysis

The 10-day RSI Indicator for AMGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 28 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 67 cases where AMGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 48%.

The Moving Average Convergence Divergence Histogram (MACD) for AMGN turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 25 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 51%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.

AMGN broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 3 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.

The Tickeron Price Growth Rating for this company is 9 (best 1 - 100 worst), indicating outstanding price growth. AMGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 15 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 33 (best 1 - 100 worst), pointing to good earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (21.297) is normal, around the industry mean (-1.421). P/E Ratio (28.386) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.524) is also within normal values, averaging (5.738). Dividend Yield (0.022) settles around the average of (0.038) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (4.033).

A.I.Advisor
a Summary for MIRA with price predictions
Nov 11, 2026

MIRA's RSI Indicator climbs out of oversold territory

The RSI Indicator for MIRA moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 22 similar instances when the indicator left oversold territory. In 22 of the 22 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MIRA as a result. In 50 of 60 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for MIRA just turned positive on November 06, 2026. Looking at past instances where MIRA's MACD turned positive, the stock continued to rise in 24 of 29 cases over the following month. The odds of a continued upward trend are 83%.

Following a +0.50% 3-day Advance, the price is estimated to grow further. Considering data from situations where MIRA advanced for three days, in 103 of 125 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.

MIRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The 10-day moving average for MIRA crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MIRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.

The Aroon Indicator for MIRA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 44 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.937) is normal, around the industry mean (-1.421). P/E Ratio (-0.468) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.738). Dividend Yield (0.000) settles around the average of (0.038) among similar stocks. MIRA's P/S Ratio (0.000) is slightly lower than the industry average of (4.033).

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. MIRA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MIRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.

FUNDAMENTALS RATINGS
AMGN: Fundamental Ratings
AMGN
OUTLOOK RATING
1..100
40
VALUATION
overvalued / fair valued / undervalued
1..100
79
Overvalued
PROFIT vs RISK RATING
1..100
3
SMR RATING
1..100
15
PRICE GROWTH RATING
1..100
9
P/E GROWTH RATING
1..100
33
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AMGNMIRA
RSI
ODDS (%)
Bearish Trend 1 day ago
61%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
48%
Bearish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
59%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
51%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
49%
Bullish Trend 1 day ago
80%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
87%
Advances
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 1 day ago
82%
Declines
ODDS (%)
Bearish Trend 9 days ago
47%
Bearish Trend 9 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
55%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
56%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (AMGN: $465.23 vs. MIRA: $0.62)
Brand notoriety: AMGN: Notable vs. MIRA: Not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: AMGN: 71% vs. MIRA: 29%
Market capitalization -- AMGN: $248.92B vs. MIRA: $23.97M
AMGN [@Pharmaceuticals: Major] is valued at $248.92B. MIRA’s [@Pharmaceuticals: Major] market capitalization is $23.97M. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $4.8K to $1.21T. The average market capitalization across the [@Pharmaceuticals: Major] industry is $215.99B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AMGN’s FA Score shows that 4 FA rating(s) are green while MIRA’s FA Score has 1 green FA rating(s).

  • AMGN’s FA Score: 4 green, 1 red.
  • MIRA’s FA Score: 1 green, 4 red.
According to our system of comparison, AMGN is a better buy in the long-term than MIRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AMGN’s TA Score shows that 5 TA indicator(s) are bullish while MIRA’s TA Score has 5 bullish TA indicator(s).

  • AMGN’s TA Score: 5 bullish, 4 bearish.
  • MIRA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, AMGN is a better buy in the short-term than MIRA.

Price Growth

AMGN (@Pharmaceuticals: Major) experienced а +0.86% price change this week, while MIRA (@Pharmaceuticals: Major) price change was +19.91% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.33%. For the same industry, the average monthly price growth was +2.53%, and the average quarterly price growth was +7.15%.

Reported Earning Dates

AMGN is expected to report earnings on Feb 09, 2027.

MIRA is expected to report earnings on Nov 12, 2026.

Industries' Descriptions

@Pharmaceuticals: Major (-1.33% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

View a ticker or compare two or three
Interact to see
Advertisement

AMGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AMGN has been loosely correlated with PFE. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if AMGN jumps, then PFE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AMGN
1D Price
Change %
AMGN100%
+0.62%
PFE - AMGN
51%
Loosely correlated
+0.31%
GILD - AMGN
48%
Loosely correlated
-0.67%
ABBV - AMGN
48%
Loosely correlated
+0.37%
BIIB - AMGN
47%
Loosely correlated
+0.06%
MRK - AMGN
47%
Loosely correlated
-0.59%
More

MIRA and

Correlation & Price change

A.I.dvisor tells us that MIRA and AMRN have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that MIRA and AMRN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIRA
1D Price
Change %
MIRA100%
+0.19%
AMRN - MIRA
20%
Poorly correlated
-0.34%
GRFS - MIRA
17%
Poorly correlated
+0.91%
SNY - MIRA
15%
Poorly correlated
+0.41%
BIIB - MIRA
11%
Poorly correlated
+0.06%
AMGN - MIRA
10%
Poorly correlated
+0.62%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AKTX7.450.32
+4.49%
Akari Therapeutics Plc
ADPT29.940.58
+1.98%
Adaptive Biotechnologies Corp
SIFY13.230.15
+1.15%
Sify Technologies Ltd
FER61.290.30
+0.49%
Ferrovial NV
TLSI2.30-0.55
-19.30%
TriSalus Life Sciences